A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Recruiting · Phase 2 · NCT04419649
Conditions: Myelodysplastic Syndromes, Cytopenia
At a glance
- Research payments reported, 2025
- $110,493
- U.S. investigators named
- 5
- Sites paid
- 5
- Planned or actual enrollment
- 210
About the trial
- Sponsor
- Takeda
- Tested
- Elritercept (drug)
- Dates
- Started 2020-08-19; completion 2031-10-30
- Results posted
- Not yet
The main aim of this study is to learn how safe elritercept is and how well adults with anemia associated with lower-risk MDS tolerate treatment with different doses of elritercept. Other aims are to learn how safe elritercept is by looking at how many participants have MDS that worsens during the study and learn about the effects of elritercept on anemia linked to MDS. The study will also look to learn how elritercept affects the production of healthy RBCs.
From ClinicalTrials.gov, last updated 2026-10-19. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Takeda Pharmaceuticals U.S.A., Inc. reported $110,493 in research payments for this study in 2025 (45 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Andrew S. Artz, M.D., M.S. Hematology · Duarte, CA
- Rami S. Komrokji, M.D. Hematology · Tampa, FL
- Mikkael A. Sekeres, MD Hematology & Oncology · Miami, FL
- Daniel Isaac, D.O. Hematology & Oncology · Grand Rapids, MI
- Robert L. Redner, MD Specialist · Pittsburgh, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Moffitt Cancer Center $34,864
- City of Hope National Medical Ctr $34,680
- Karmanos Cancer Center, MI $23,329
- University of Miami Hospital $10,620
- University of Pittsburgh Cancer Institute Cancer Services $7,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.